Skip to main content
Erschienen in: Thyroid Research 1/2015

Open Access 01.12.2015 | Meeting abstract

Reference ranges for TSH and thyroid hormones

verfasst von: Krzysztof Lewandowski

Erschienen in: Thyroid Research | Sonderheft 1/2015

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Though TSH remains the most commonly used endocrine test in clinical practice, the issue of an appropriate TSH, and to a lesser extent, free T4 and free T3 reference ranges is still under debate. First of all the distribution of TSH reference range is not normal, with median values (also depending on population iodine intake) usually between 1-1.5 mU/L [13]. On the other hand, upper TSH reference limit is (assay-dependent) usually around 4.2-4.5 mU/L. There is also an argument that significant number of patients (up to 30%) with TSH above 3.0 mU/L have an occult autoimmune thyroid disease [4]. On the other hand the upper normal TSH reference range in elderly subjects (i.e. 70 plus years) may extend up to around 6.0 mU/L, with relative small changes in free hormones. This phenomenon also applies to elderly patients, where autoimmune thyroid disease had been ruled out [1, 2]. Furthermore, there is little evidence of any adverse effects of autoimmune thyroid disease in the elderly in the absence of an overt hypothyroidism. Indeed, Wang et al [5] surprisingly demonstrated decreased frailty in elderly subjects with raised titres of thyroid autoantibodies. It is also well known that in the setting of subclinical hypothyroidism, concentrations of free T4 start to decline below 10 pmol/L only with TSH above 6-7 mU/L in elderly subjects, though a decline in free T4 is more pronounced in the young (particularly in those aged 20-29 years), where free T4 starts to decline for TSH concentrations above 4.5 mU/l [6]. Another issue pertains to the risk of cardiovascular disease in subjects with subclinical hypothyroidism. There are data from post-menopausal women enrolled into the Women Health Initiative study, where an increase in the risk of myocardial infarction was demonstrated only for TSH concentrations above 7.0 mU/L [7].
A separate issue, extensively discussed elsewhere [8], pertains to alterations of TSH and free thyroid hormones during pregnancy. In particular there is decrease in TSH in the first trimester followed by a gradual return to pre-pregnancy values. In contrast, there is an increase in free T4 in the first trimester, while in the third trimester free T4 concentrations are usually at the lower end of the standard (i.e. pre-pregnancy) reference range, or even just below the lower reference limit. Hence, there is an urgent need (postulated in the Endocrine Society Guidelines [8]) to create separate reference ranges for TSH and free thyroid hormones during pregnancy, possible with reference to each trimester. There are also recent data from China [9], where the authors demonstrated that the above-mentioned first trimester-related alterations in TSH and free T4, become only really visible after about 5th-6th week of gestation. The authors of this study suggest that standard reference ranges for TSH and free T4 can be applied up to this point of gestation.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
download
DOWNLOAD
print
DRUCKEN
Literatur
1.
Zurück zum Zitat Fontes R, Coeli CR, Aguiar F, Vaisman M: Reference interval of thyroid stimulating hormone and free thyroxine in a reference population over 60 years old and in very old subjects (over 80 years): comparison to young subjects. Thyroid Res 2013,6(1):13. 10.1186/1756-6614-6-13PubMedCentralPubMedCrossRef Fontes R, Coeli CR, Aguiar F, Vaisman M: Reference interval of thyroid stimulating hormone and free thyroxine in a reference population over 60 years old and in very old subjects (over 80 years): comparison to young subjects. Thyroid Res 2013,6(1):13. 10.1186/1756-6614-6-13PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Vadiveloo T, Donnan PT, Murphy MJ, Leese GP: Age- and Gender-Specific TSH Reference Intervals in People With No Obvious Thyroid Disease in Tayside, Scotland: The Thyroid Epidemiology, Audit, and Research Study (TEARS). J Clin Endocrinol Metab 2013,98(3):1147–1153. 10.1210/jc.2012-3191PubMedCrossRef Vadiveloo T, Donnan PT, Murphy MJ, Leese GP: Age- and Gender-Specific TSH Reference Intervals in People With No Obvious Thyroid Disease in Tayside, Scotland: The Thyroid Epidemiology, Audit, and Research Study (TEARS). J Clin Endocrinol Metab 2013,98(3):1147–1153. 10.1210/jc.2012-3191PubMedCrossRef
3.
Zurück zum Zitat Biondi B: The Normal TSH Reference Range: What Has Changed in the Last Decade? J Clin Endocrinol Metab 2013,98(9):3584–3587. 10.1210/jc.2013-2760PubMedCrossRef Biondi B: The Normal TSH Reference Range: What Has Changed in the Last Decade? J Clin Endocrinol Metab 2013,98(9):3584–3587. 10.1210/jc.2013-2760PubMedCrossRef
4.
Zurück zum Zitat Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE: National Health and Nutrition Examination Survey III: Thyroid-Stimulating Hormone (TSH)-Thyroperoxidase Antibody Relationships Demonstrate That TSH Upper Reference Limits May Be Skewed by Occult Thyroid Dysfunction. J Clin Endocrinol Metab 2007,92(11):4236–4240. 10.1210/jc.2007-0287PubMedCrossRef Spencer CA, Hollowell JG, Kazarosyan M, Braverman LE: National Health and Nutrition Examination Survey III: Thyroid-Stimulating Hormone (TSH)-Thyroperoxidase Antibody Relationships Demonstrate That TSH Upper Reference Limits May Be Skewed by Occult Thyroid Dysfunction. J Clin Endocrinol Metab 2007,92(11):4236–4240. 10.1210/jc.2007-0287PubMedCrossRef
5.
Zurück zum Zitat Wang GC, Talor MV, Rose NR, Cappola AR, Chiou RB, Weiss C, et al.: Thyroid autoantibodies are associated with a reduced prevalence of frailty in community-dwelling older women. J Clin Endocrinol Metab 2010,95(3):1161–1168. 10.1210/jc.2009-1991PubMedCentralPubMedCrossRef Wang GC, Talor MV, Rose NR, Cappola AR, Chiou RB, Weiss C, et al.: Thyroid autoantibodies are associated with a reduced prevalence of frailty in community-dwelling older women. J Clin Endocrinol Metab 2010,95(3):1161–1168. 10.1210/jc.2009-1991PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Hadlow NC, Rothacker KM, Wardrop R, Brown SJ, Lim EM, Walsh JP: The Relationship Between TSH and Free T4 in a Large Population Is Complex and Nonlinear and Differs by Age and Sex. J Clin Endocrinol Metab 2013,98(7):2936–2943. 10.1210/jc.2012-4223PubMedCrossRef Hadlow NC, Rothacker KM, Wardrop R, Brown SJ, Lim EM, Walsh JP: The Relationship Between TSH and Free T4 in a Large Population Is Complex and Nonlinear and Differs by Age and Sex. J Clin Endocrinol Metab 2013,98(7):2936–2943. 10.1210/jc.2012-4223PubMedCrossRef
7.
Zurück zum Zitat LeGrys VA, Funk MJ, Lorenz CE, Giri A, Jackson RD, Manson JE, Schectman R, Edwards TL, Heiss G, Hartmann KE: Subclinical Hypothyroidism and Risk for Incident Myocardial Infarction Among Postmenopausal Women. J Clin Endocrinol Metab 2013,98(6):2308–2317. 10.1210/jc.2012-4065PubMedCentralPubMedCrossRef LeGrys VA, Funk MJ, Lorenz CE, Giri A, Jackson RD, Manson JE, Schectman R, Edwards TL, Heiss G, Hartmann KE: Subclinical Hypothyroidism and Risk for Incident Myocardial Infarction Among Postmenopausal Women. J Clin Endocrinol Metab 2013,98(6):2308–2317. 10.1210/jc.2012-4065PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al.: Management of Thyroid Dysfunction during Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2012,97(8):2543–2565. 10.1210/jc.2011-2803PubMedCrossRef De Groot L, Abalovich M, Alexander EK, Amino N, Barbour L, Cobin RH, et al.: Management of Thyroid Dysfunction during Pregnancy and Postpartum: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2012,97(8):2543–2565. 10.1210/jc.2011-2803PubMedCrossRef
9.
Zurück zum Zitat Li C, Shan Z, Mao J, Wang W, Xie X, Zhou W, et al.: Assessment of Thyroid Function During First- Trimester Pregnancy: What Is the Rational Upper Limit of Serum TSH During the First Trimester in Chinese Pregnant Women? J Clin Endocrinol Metab 2014,99(1):73–79. 10.1210/jc.2013-1674PubMedCrossRef Li C, Shan Z, Mao J, Wang W, Xie X, Zhou W, et al.: Assessment of Thyroid Function During First- Trimester Pregnancy: What Is the Rational Upper Limit of Serum TSH During the First Trimester in Chinese Pregnant Women? J Clin Endocrinol Metab 2014,99(1):73–79. 10.1210/jc.2013-1674PubMedCrossRef
Metadaten
Titel
Reference ranges for TSH and thyroid hormones
verfasst von
Krzysztof Lewandowski
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Thyroid Research / Ausgabe Sonderheft 1/2015
Elektronische ISSN: 1756-6614
DOI
https://doi.org/10.1186/1756-6614-8-S1-A17

Weitere Artikel der Sonderheft 1/2015

Thyroid Research 1/2015 Zur Ausgabe

Meeting abstract

Antithyroid drugs

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.